Evotec Prepares for Pivotal AGM as Restructuring Accelerates and Key Technical Levels Loom
31.05.2026 - 05:34:02 | boerse-global.de
Evotec enters a defining week with its annual general meeting on June 11 in Hamburg, where a reshaped board, a new compensation framework, and a performance share plan will dominate the agenda — just as the company’s deeper operational overhaul gathers pace. The stock closed Friday at €5.25, gaining roughly three percent and reclaiming its 50-day moving average at €4.91, a modest technical win for a share that has fallen 23 percent over the past year and remains nearly seven percent below the 200-day line at €5.65.
Board expansion and governance shake-up
The AGM will see the supervisory board grow from six to seven members, with Dieter Weinand nominated to take the chair. Dr. Wolfgang Hofmann, Duncan McHale, and Wesley Wheeler are also up for election alongside four continued members. A new remuneration system and the introduction of a Performance Share Plan 2026 will be put to a vote, while the existing executive team — CEO Dr. Christian Wojczewski, Dr. Cord Dohrmann, and Aurélie Dalbiez — recently received restricted share awards tied to the 2025 financial year, aligning their incentives with shareholder returns during the ongoing Horizon transformation.
Investors will also scrutinise the capital structure. A conditional capital increase in May triggered a mandatory disclosure under the German Securities Trading Act, showing total voting rights now stand at 177,907,695 shares. The company’s €116.1 million convertible bond remains a key financing pillar.
Horizon restructuring on a tight timeline
The Horizon cost-cutting programme, launched in March 2026, aims to reduce Evotec’s annual cost base by approximately €75 million by the end of 2027. The plan involves halving the number of sites from 19 to 10. First-quarter provisions of €75 million were set aside, primarily for severance and asset impairments.
Should investors sell immediately? Or is it worth buying Evotec?
Those savings are sorely needed. First-quarter revenue slipped to €156.6 million, while adjusted EBITDA swung from a positive €3.1 million a year earlier to a loss of €21.9 million — though that comparison is distorted by a one-off license sale to Sandoz in the prior period. Management has guided for full-year revenue in the range of €700 million to €780 million and adjusted EBITDA between €0 and €40 million, with an operational improvement expected in the second half.
Technical signs and a pending index return
From March’s 52-week low of €4.14, the stock has recovered 27 percent, though it still sits roughly 30 percent below the year’s peak of €7.54. The relative strength index at just under 60 signals moderate bullish momentum without overheating. A sustained hold above €5.20 could open the path toward the next resistance zone around €5.50, though the 200-day moving average at €5.65 remains the key hurdle for a genuine technical breakout.
Adding structural tailwinds, Evotec is set to re-enter the MDAX index in June, boosting its visibility among institutional investors and potentially driving new ETF inflows. The restoration was announced after the company’s temporary demotion, and it provides a fresh catalyst ahead of the AGM.
Evotec at a turning point? This analysis reveals what investors need to know now.
Conference circuit and collaboration cues
On the business development front, Evotec is currently presenting at the 74th ASMS conference in San Diego, showcasing advances in analytics and proteomics critical to early-stage drug discovery. From June 3 in Seattle, the BioCentury Grand Rounds will serve as another forum to highlight platform technologies and therapeutic strategies. Market observers will watch for any partnership announcements — the collaboration with Bristol Myers Squibb most recently yielded a $25 million neuroscience milestone payment in October 2025.
With the AGM now days away, Evotec’s narrative is a blend of governance renewal, aggressive cost discipline, and a tentative technical recovery. The coming weeks will test whether the strategy can translate into tangible operational progress.
Ad
Evotec Stock: New Analysis - 31 May
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
